TheraSonic

What TheraSonic does

TheraSonic SAS is a Paris-based medical technology company founded in 2023 and spun out of over fifteen years of academic research conducted at France's CEA and CNRS. The company is developing a single core product — a non-invasive robotic medical device that uses low-intensity focused ultrasound combined with injected microbubbles to transiently disrupt the blood-brain barrier (BBB), enabling targeted delivery of therapeutic agents (including gene therapies) to specific brain regions. The platform integrates three proprietary technical pillars: a real-time dosimetry solution for safe, repeatable BBB disruption; a state-of-the-art neuro-navigation system for precision targeting; and a medical robot that enables treatment of multiple targets and large tissue volumes in a single session. The BBB effect is reversible, restoring integrity within hours to days, which underpins repeated treatment protocols.

TheraSonic targets neurological disease treatment centers — hospitals and neuro-oncology / neurology clinics — as its B2B customer base. Its intended indication footprint is broad, spanning brain metastases and primary brain tumors as the lead focus, alongside neurodegenerative conditions including Parkinson's, Huntington's, and Alzheimer's disease, as well as ALS and other disorders where drug delivery to the brain is the limiting treatment bottleneck. The GTM motion is enterprise field sales into hospitals and clinical centers for clinical trials and eventual commercial deployment.

Commercially, TheraSonic is pre-revenue with no disclosed pricing or commercial sales. The company is funded by a €1 million pre-seed round completed in May 2024 and led by M2care with participation from Gustave Roussy Transfert, and has announced a second round targeted for summer 2026. The team of roughly five PhD-level leaders is complemented by a strategic committee chaired by Geraldine Le Duc and including representatives from M2care and Gustave Roussy Transfert, providing both clinical-expert and institutional investor oversight as the company prepares for clinical trials and regulatory clearance.

Name

TheraSonic

Legal name

TheraSonic SAS

Website

https://therasonic.fr

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

TheraSonic is a Paris-based medical device startup developing a non-invasive robotic platform that uses focused ultrasound and microbubbles to temporarily disrupt the blood-brain barrier, enabling targeted drug delivery for neurological diseases including brain tumors and neurodegenerative disorders.

Ownership category

akta.pro rank

Product category

Neuromodulation & Focused Ultrasound Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC)

Keywords

• Focused ultrasound devices
• Blood-brain barrier disruption
• Neuro drug delivery
• Medical robotics
• Neurological disease treatment

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Medical device sales: Pre-revenue company. Plans to commercialize robotic medical device for focused ultrasound-guided drug delivery to the brain. Initial target: brain metastases and neurological conditions such as brain tumors, neurodegenerative diseases (Parkinson's, Huntington's, Alzheimer's), and ALS.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

TheraSonic develops a non-invasive robotic medical device that uses low-intensity focused ultrasound combined with microbubbles to transiently disrupt the blood-brain barrier, enabling targeted delivery of therapeutic agents to specific brain regions. The platform integrates real-time dosimetry, neuro-navigation, and medical robotics to safely and precisely treat neurological diseases including brain metastases, brain tumors, neurodegenerative disorders (Parkinson's, Huntington's, Alzheimer's), and ALS.

Product overview

TheraSonic offers a single unified medical device product focused on non-invasive brain drug delivery using focused ultrasound technology. The system consists of a robotic platform with real-time dosimetry and neuro-navigation capabilities that enables transient disruption of the blood-brain barrier when combined with injected microbubbles, allowing therapeutics to reach targeted brain regions.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• BBB naturally restores integrity within hours to days after treatment

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CEA (Commissariat à l'énergie atomique et aux énergies alternatives)coreStrategic or Co-development PartnerFrench Alternative Energies and Atomic Energy Commission. TheraSonic originated as a spin-off from CEA and CNRS research with over 15 years of academic research backing the technology. Featured at VivaTech 2025 by CEA.
• CNRS (Centre National de la Recherche Scientifique)coreStrategic or Co-development PartnerFrench National Centre for Scientific Research. Co-originator of the technology and research behind TheraSonic's focused ultrasound platform.
• Paris Saclay Cancer ClusterminorOthersSupport organization for cancer research and innovation ecosystem in Paris-Saclay region.
• BPI FranceminorOthersFrench public investment bank providing support for innovative companies.
• MedicenminorOthersParis Region healthcare competitiveness cluster supporting innovative healthtech companies.
• La French Tech Paris-SaclayminorOthersFrench Tech initiative supporting startups in the Paris-Saclay ecosystem.
• France BiotechminorOthersFrench healthcare biotechnology industry association that awarded TheraSonic the Trophée Jeune Entreprise HealthTech 2026.
• Matwin / Angels SanteminorGTM or Marketing PartnerOncology-focused business development platform. Selected TheraSonic to pitch at Oncology Upward Investment event in Bordeaux.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Carthera: French clinical-stage company developing the SonoCloud implantable ultrasound device for transient blood-brain barrier opening to enable drug delivery in brain tumors and neurodegenerative diseases. Closest direct competitor — same application (BBB disruption), same core modality (focused ultrasound + microbubbles), same French medtech ecosystem.

Broad incumbents

• Insightec: Israeli-founded global leader in MR-guided focused ultrasound (Exablate Neuro) with FDA-cleared applications in essential tremor, Parkinson's tremor, and oncology. Broad incumbent in focused ultrasound with overlapping brain therapy ambition and far greater capital and clinical footprint.
• Profound Medical: Commercial-stage developer of TULSA-PRO (transurethral ultrasound ablation) and the Sonalleve MR-HIFU platform. Broad incumbent in therapeutic focused ultrasound with overlapping modality and engineering requirements, but focused on prostate and uterine fibroids rather than brain.
• EDAP TMS: French-listed company commercializing therapeutic ultrasound platforms including Focal One (HIFU for prostate) and Ablatherm. Broad incumbent in clinical focused ultrasound with shared engineering, regulatory, and European medtech commercial pathways.
• NovoCure: Commercial-stage global oncology company using Tumor Treating Fields (TTFields) for glioblastoma and other solid tumors. Adjacent incumbent in non-invasive brain tumor treatment modality with overlapping hospital neuro-oncology buyers.

Emerging players

• NaviFUS: Taiwan-based clinical-stage company developing transcranial focused ultrasound for non-invasive BBB opening and sonodynamic therapy in brain tumors and neurological diseases. Comparable technology approach (non-invasive FUS for drug delivery) but emerging-stage with regional (Asia-Pacific) footprint.
• HistoSonics: US-based commercial-stage company developing histotripsy (non-thermal mechanical focused ultrasound) for non-invasive tissue destruction, currently in liver tumors with expansion ambitions. Emerging player with shared non-invasive FUS technology base but different clinical application.
• SonALAsense: US clinical-stage company developing sonodynamic therapy — using focused ultrasound to activate systemic drugs in the brain for glioma and other CNS tumors. Emerging player with overlapping brain-focused ultrasound + drug activation approach.
• Inbrain Neuroelectronics: European clinical-stage neurotechnology company developing graphene-based neural interfaces for brain disorders. Comparable as a deep-tech European neuro medtech raising growth capital to bridge from preclinical to clinical, though addressing different modality (implants vs. non-invasive FUS).

Others

• Collagen Solutions: Not a direct competitor, but illustrative of an early/clinical-stage European medtech targeting CNS applications — useful comparable for the capital-raising and partnering trajectory TheraSonic is on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/therasonic

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraSonic